# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Legend Biotech (NASDAQ:LEGN) with a Buy and lowers the price ta...
JP Morgan analyst Jessica Fye maintains Legend Biotech (NASDAQ:LEGN) with a Overweight and lowers the price target from $78 ...
Legend Biotech USA Inc. Enters into Component and Product Supply Agreement with Janssen Pharmaceuticals, Inc.On October 6, 2025...
https://www.bloomberg.com/news/articles/2025-09-05/legend-biotech-is-said-to-explore-second-listing-outside-of-us
Cantor Fitzgerald analyst Eric Schmidt assumes Legend Biotech (NASDAQ:LEGN) with a Overweight rating and announces Price Tar...